Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Innovent Biologics ( (HK:1801) ) has shared an update.
Innovent Biologics announced the grant of 20,800 share options to five grantees, including Dr. Sherwin, an independent non-executive director, as part of its 2024 Share Scheme. This move aims to incentivize employees and directors, with options vesting over several years and tied to performance targets for non-executive employees. The grant reflects the company’s strategy to align employee and director interests with its long-term goals, potentially impacting its operational focus and stakeholder engagement.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$114.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development, manufacturing, and commercialization of medicines. The company is listed on the Hong Kong Stock Exchange and is involved in innovative drug development, particularly in the fields of oncology, metabolic, autoimmune, and other major diseases.
Average Trading Volume: 24,539,636
Technical Sentiment Signal: Buy
Current Market Cap: HK$155.3B
For detailed information about 1801 stock, go to TipRanks’ Stock Analysis page.